Drug
Adderall-XR
Adderall-XR is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
1
20%
Ph phase_2
3
60%
Ph early_phase_1
1
20%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 23 (60.0%)
Trials by Status
terminated120%
enrolling_by_invitation120%
completed360%
Recent Activity
0 active trials
Showing 5 of 5
enrolling_by_invitationearly_phase_1
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
NCT04509102
completedphase_1
Biomarkers of ADHD Treatment Response
NCT05650775
completedphase_2
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
NCT02803229
completedphase_2
Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
NCT00553319
terminatedphase_2
Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
NCT00069927
Clinical Trials (5)
Showing 5 of 5 trials
NCT04509102Early Phase 1
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
NCT05650775Phase 1
Biomarkers of ADHD Treatment Response
NCT02803229Phase 2
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
NCT00553319Phase 2
Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
NCT00069927Phase 2
Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5